Does Type of Tumor Histology Impact Survival among Patients with Stage IIIB/IV Non-Small Cell Lung Cancer Treated with First-Line Doublet Chemotherapy?
| Autor: | Joshua Nyambose, David M. Thompson, KM Clements, Craig C. Earle, Martin D. Marciniak, Gerson Peltz, Kathleen Lang, Douglas E. Faries, Douglas C.A. Taylor, Katherine P. Sugarman |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Cisplatin
Oncology Chemotherapy medicine.medical_specialty Pathology Taxane Article Subject business.industry medicine.medical_treatment Histology General Medicine medicine.disease behavioral disciplines and activities Carboplatin Gemcitabine Cancer registry chemistry.chemical_compound chemistry Internal medicine medicine Lung cancer business Research Article medicine.drug |
| Zdroj: | Chemotherapy Research and Practice |
| ISSN: | 2090-2115 2090-2107 |
| DOI: | 10.1155/2010/524629 |
| Popis: | Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients (N=2,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and cisplatin/carboplatin plus a taxane (C/C+T) identified retrospectively in the SEER cancer registry (1997–2002). Patients with squamous and nonsquamous cell carcinoma survived 8.5 months and 8.1 months, respectively (P=.018). No statistically significant difference was observed in survival between C/C+G and C/C+T in both histologies. Adjusting for clinical and demographic characteristics, the effect of treatment regimen on survival did not differ by histology (P for interaction =.257). There was no statistically significant difference in hazard of death by histology in both groups. These results contrast the predictive role of histology and improved survival outcomes observed for cisplatin-pemetrexed regimens in advanced nonsquamous NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|